Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Three are better than one: plasminogen receptors as cancer theranostic targets.

Ceruti P, Principe M, Capello M, Cappello P, Novelli F.

Exp Hematol Oncol. 2013 Apr 17;2(1):12. doi: 10.1186/2162-3619-2-12.

2.

New Insight on the Role of Plasminogen Receptor in Cancer Progression.

Kumari S, Malla R.

Cancer Growth Metastasis. 2015 Jul 29;8:35-42. doi: 10.4137/CGM.S27335. eCollection 2015. Review.

3.

α-Enolase: a promising therapeutic and diagnostic tumor target.

Capello M, Ferri-Borgogno S, Cappello P, Novelli F.

FEBS J. 2011 Apr;278(7):1064-74. doi: 10.1111/j.1742-4658.2011.08025.x. Epub 2011 Feb 24. Review.

4.

The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.

Sharma MC, Sharma M.

Curr Pharm Des. 2007;13(35):3568-75. Review.

PMID:
18220793
5.

Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.

Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo CC, Chu PY, Hung YM, Chou SW, Yang YY, Chang GC, Liu KJ.

PLoS One. 2013 Jul 19;8(7):e69354. doi: 10.1371/journal.pone.0069354. Print 2013.

6.

[The clinical prospects for the study of the plasminogen activation system in breast cancer].

Gershteĭn ES, Kushlinskiĭ NE.

Vestn Ross Akad Med Nauk. 1999;(8):58-61. Review. Russian.

PMID:
10487126
7.

Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.

Li P, Gao Y, Ji Z, Zhang X, Xu Q, Li G, Guo Z, Zheng B, Guo X.

J Pediatr Surg. 2004 Oct;39(10):1512-9.

PMID:
15486896
8.

S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.

Kwon M, MacLeod TJ, Zhang Y, Waisman DM.

Front Biosci. 2005 Jan 1;10:300-25. Print 2005 Jan 1. Review.

PMID:
15574370
9.
10.

Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.

He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, Dong JH, Li X.

Clin Cancer Res. 2007 Jun 1;13(11):3115-24.

11.

Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.

Principe M, Ceruti P, Shih NY, Chattaragada MS, Rolla S, Conti L, Bestagno M, Zentilin L, Yang SH, Migliorini P, Cappello P, Burrone O, Novelli F.

Oncotarget. 2015 May 10;6(13):11098-113.

12.

Urokinase plasminogen activator receptor (CD87): something old, something new.

Ge Y, Elghetany MT.

Lab Hematol. 2003;9(2):67-71. Review.

PMID:
12828301
13.

The role of plasminogen-plasmin system in cancer.

Kwaan HC, McMahon B.

Cancer Treat Res. 2009;148:43-66. doi: 10.1007/978-0-387-79962-9_4. Review.

PMID:
19377918
15.

Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation.

Capello M, Caorsi C, Bogantes Hernandez PJ, Dametto E, Bertinetto FE, Magistroni P, Rendine S, Amoroso A, Novelli F.

Immunol Lett. 2015 Sep;167(1):11-6. doi: 10.1016/j.imlet.2015.06.008. Epub 2015 Jun 18.

16.

Evolving role of uPA/uPAR system in human cancers.

Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH.

Cancer Treat Rev. 2008 Apr;34(2):122-36. Epub 2007 Dec 26. Review.

PMID:
18162327
17.
18.

Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.

Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW.

J Clin Oncol. 1995 Aug;13(8):2084-93.

PMID:
7636552
19.

Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease.

Godier A, Hunt BJ.

J Thromb Haemost. 2013 Jan;11(1):26-34. doi: 10.1111/jth.12064. Review.

20.

Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.

Choong PF, Nadesapillai AP.

Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S46-58. Review.

PMID:
14600592

Supplemental Content

Support Center